Viatical + Life Settlements — Selling a Policy on the Secondary Market (2026)

Last updated May 2026 · Rate Authority.

Viatical + Life Settlements — Selling a Policy on the Secondary Market

A life insurance policy is a financial asset. It can be sold. A viatical or life settlement is the transaction that turns a policy into immediate cash: a third-party buyer pays the policyowner a lump sum, assumes ongoing premium obligations, and collects the death benefit when the insured dies. The spread between what the buyer pays today and the death benefit they eventually collect is their return. The policyowner trades future value for present liquidity.

The market’s origin is specific. In the mid-1980s, insureds dying of AIDS held life insurance they could not afford to keep and whose surrender values were negligible compared to face amounts. A secondary market emerged to buy those policies. Buyers accepted a shorter life expectancy in exchange for a larger spread. The transaction had a defined name — viatical settlement — and a coherent logic. Over the following two decades the market expanded: life settlements now encompass policies held by seniors with ordinary life expectancies who simply no longer want or can afford coverage. Same transaction structure, materially different economics and tax treatment.

Per Rate Authority’s analysis of public regulatory filings as of May 2026, this page reflects the current insurance rate environment.

(Source: Rate Authority, May 2026.)

Viatical vs. Life Settlement — The IRC §101(g) Distinction

The Internal Revenue Code draws a hard line between these two categories, and the tax consequences depend on which side of it the insured falls on.

Viatical settlement — defined by reference to IRC §101(g)(2). The insured must be certified by a physician as either terminally ill (life expectancy of 24 months or fewer under normal circumstances) or chronically ill within the meaning of §7702B (unable to perform at least two activities of daily living, or requiring substantial supervision due to severe cognitive impairment). A licensed viatical settlement provider — a term of art under both the IRC and state insurance law — must be the buyer.

When those conditions are met, proceeds are treated as an accelerated death benefit under IRC §101(g) and excluded from gross income. The full settlement amount is tax-free to the policyowner. For chronically ill insureds there is a per-diem cap (adjusted annually by the IRS), but terminal illness cases face no such limit: the entire viatical payment is excluded.

Life settlement — the insured does not meet the terminal or chronic illness thresholds. Tax-free treatment does not apply. The tax consequence tracks basis, surrender value, and face amount in three tiers:

1. Proceeds up to the policy’s cost basis (total premiums paid less any dividends received tax-free) are returned tax-free.
2. Proceeds above basis but no greater than the cash surrender value at time of sale are ordinary income.
3. Proceeds above the surrender value — the portion that reflects the secondary-market premium — are long-term capital gain.

The Tax Cuts and Jobs Act of 2017 simplified the life settlement taxation framework and codified this three-tier treatment. Pre-2018 the analysis was more complex. Post-2018 the capital-gain tier is now established, which matters for policies with significant face value and low ongoing premium burden — exactly the policies where settlement offers tend to be highest.

The difference in tax treatment between a viatical settlement and a life settlement on a comparable policy can be substantial. An attorney or CPA should confirm classification before any settlement transaction closes.

Market Structure

Five distinct parties participate in a standard settlement transaction.

The policyowner/seller. Usually the named insured (or a trust or business that owns the policy). They initiate the transaction, provide medical records for LE underwriting, and receive the settlement proceeds.

The broker. Represents the policyowner’s interests. A properly functioning broker solicits competing bids from multiple licensed providers, presents them to the policyowner, and helps evaluate terms. Brokers are compensated by commission, typically 6 to 8 percent of the gross settlement value — a number that should appear in pre-transaction disclosures. Broker compensation structures create a potential conflict: brokers who earn percentage-based commissions from providers have an incentive to maximize offer size rather than necessarily steer sellers toward the most appropriate option. State disclosure requirements exist specifically to surface this tension.

The provider. The entity that actually purchases the policy. Providers must be licensed in the seller’s state of residence in most jurisdictions. They fund the purchase price, assume premium payments, and own the policy. Many providers are funds or institutional investors rather than individual buyers; the provider is frequently an intermediary between the seller and the ultimate capital.

The servicer. After a policy is sold, a servicer tracks premium due dates, pays premiums to keep the policy in force, monitors the insured’s status (legally, through periodic contact and public record searches), and initiates the death benefit claim. Servicer fees come out of the provider’s economics, not the policyowner’s proceeds.

The investor. The capital behind the provider’s portfolio. Institutional investors — hedge funds, pension funds, family offices — buy pools of policies as fixed-income-adjacent alternative assets. Their required return shapes the discount rates providers apply when pricing offers.

Pricing — What Determines the Offer

Settlement offers are a function of several interacting variables. Understanding them explains why offers vary substantially across providers for identical policies.

Life expectancy estimates drive more of the pricing than anything else. An LE of 36 months produces a meaningfully higher offer than an LE of 84 months for the same face value and premium. LE is estimated either through physician certification or through specialized LE underwriting firms that apply actuarial tables to the insured’s medical history. These estimates are inherently uncertain; they are probability distributions, not predictions.

The gap between the cash surrender value and the settlement offer represents the economic value the secondary market creates for policyowners. On policies where the insured has shortened life expectancy or where the policy has low premiums relative to face value, this gap can be large. On policies where surrender value already approximates face value, or where premiums are high relative to the benefit, the gap may be small or the offer unattractive.

State Regulatory Framework

Viatical and life settlements are regulated at the state level through insurance departments, not the SEC or FINRA. Two NAIC model laws govern the primary framework most states have drawn from: the NAIC Viatical Settlements Model Act and the separate NAIC Life Settlements Model Act. These are distinct instruments with separate histories, though many states have folded both into consolidated settlement statutes.

More than 43 states regulate viatical or life settlements at the DOI level in some form. Regulatory density varies. Key requirements that appear across most major state frameworks:

Licensure. Brokers and providers must be licensed in the seller’s state of residence, and in some states also the insured’s state if they differ. Selling through an unlicensed party is a consumer-protection violation.

Pre-transaction disclosure. Before a settlement closes, the policyowner must receive written disclosure of: the offer amount and fees, the broker’s compensation, the alternative options the seller may not have considered (carrier accelerated death benefits, policy loans, 1035 exchange), and the fact that settlement proceeds may be taxable. Disclosure requirements exist because historically the consumer-protection failures in this market occurred when policyowners did not understand what they were transacting.

Rescission period. Most state frameworks provide a rescission window after closing — typically 15 to 30 days — during which the policyowner can cancel the transaction and return proceeds.

Medical privacy. HIPAA governs the transmission and handling of the insured’s medical records used in LE underwriting. State privacy statutes add additional layers. The insured must consent to ongoing status monitoring by the servicer post-sale.

Anti-fraud provisions. Regulations prohibit stranger-originated life insurance (STOLI) — policies purchased on a stranger’s life with the intent from inception to sell them. STOLI was the central abuse pattern of the 2000s-era fraud wave; it remains the primary category state regulators and prosecutors pursue.

When a Settlement Makes Sense for the Policyowner

Four scenarios where a settlement has legitimate logic:

The policy is genuinely no longer needed. Estate plans change. Children are grown, the business was sold, the mortgage is paid. A policy purchased for income-replacement or estate-liquidity purposes may have served its function. Surrendering for CSV leaves money on the table if a secondary market exists for the policy. Settlement converts that policy to its full market value.

Premiums are no longer affordable and lapse is imminent. A policy that lapses returns nothing (or the modest CSV). A settlement in advance of lapse recovers more than zero. Even a modest settlement offer relative to face value is a better outcome than unrecovered premiums.

The insured has shortened life expectancy. This is the original viatical scenario and still the most favorable economics for the seller. Short LE creates a large spread between settlement value and CSV. The §101(g) tax exclusion for terminal illness eliminates the ordinary-income and capital-gain exposure. The calculus is different from a general life settlement and should be analyzed separately.

The insured is chronically ill and needs current income. §101(g) also covers chronic illness as defined in §7702B. Tax-free proceeds under viatical treatment can fund care costs that would otherwise deplete other assets.

When It Does Not Make Sense

The policy still serves an insurance need. Dependents, estate-tax liquidity, business succession obligations, or spousal income replacement are not cured by selling the policy. Settlement is a permanent transfer. The insurance need does not disappear because the policy is gone.

Surrender value already approximates face value. This occurs primarily with paid-up whole life policies in later years. There is little spread for a buyer to capture; settlement offers will be thin or non-existent.

Long life expectancy with high ongoing premiums. The buyer’s required IRR demands a meaningful spread between what they pay and what they eventually collect, after accounting for all premium payments along the way. Long LE and high premiums compress that spread. The offer will be unattractive.

Alternatives were not explored first. The two most important alternatives are frequently overlooked:

• Carrier accelerated death benefits (ADB). Many life insurance policies include an ADB rider that allows the policyowner to collect a portion of the death benefit early upon terminal illness certification. ADB proceeds are also treated as tax-free under §101(g) when terminal illness criteria are met, and the rider is typically built into the policy at no additional premium cost. A policyowner eligible for a viatical settlement should confirm whether the carrier’s own ADB terms are comparable before selling the policy to a third party.

• Policy loan. For cash-value policies with substantial accumulated value, a policy loan provides liquidity without surrendering the death benefit. The loan accrues interest, and if the policy lapses with an outstanding loan, taxable income may result — but for a policyowner who needs near-term cash without permanently transferring the policy, a loan is worth modeling.

The Consumer-Protection Problems That Drove Regulation

State regulation of settlements did not emerge from abstract policy concerns. It emerged from documented market failures.

The 1990s–2000s fraud wave. The early viatical market attracted operators who pooled investor money to buy policies. Some pooled funds were fraudulent: policies were fabricated, insured identities were misrepresented, or operators collected investor money and simply did not deploy it into legitimate policies. Investors lost; policyowners in legitimate transactions were caught in the fallout. The SEC and state regulators pursued criminal and civil cases throughout this period.

Life expectancy manipulation. For both fraudulent and aggressive-but-legal operators, inflated LE estimates (suggesting insureds would live longer than they actually would) allowed operators to pay less to policyowners while marketing policies to investors as if they were fairly priced. The asymmetry of information between the operator conducting LE underwriting and the policyowner receiving the offer is structural. Disclosure requirements and independent LE review emerged as partial corrections.

STOLI schemes. Stranger-originated life insurance involved inducing seniors to take out new life insurance policies — sometimes with investor-funded premiums — with the agreement that the policies would be sold to investors after the two-year contestability period expired. STOLI is insurance fraud: the insured had no insurable interest in the arrangement from inception. It also violated the public policy underpinning life insurance. Most states codified explicit STOLI prohibitions following a wave of prosecutions in the mid-2000s.

The “free money” sales pitch. Settlement brokers sometimes approach seniors with pitches that characterize an unwanted policy as a hidden asset requiring only a simple transaction to unlock. The pitch is not entirely wrong — secondary market value does exist and does exceed surrender value in legitimate cases — but the framing obscures the tax consequences of life settlements, the cost structure, and the alternatives. Pre-transaction disclosure requirements exist to break the information asymmetry before the policyowner commits.

Three Common Misapplications

Skipping the carrier’s ADB rider. A terminally ill policyowner presented with a viatical settlement offer should verify whether the carrier offers its own accelerated death benefit, at what percentage of face value, and under what conditions. Carriers frequently offer 50 to 90 percent of the death benefit as ADB for terminal illness certification. The ADB route eliminates the broker’s commission, keeps the transaction between the policyowner and their carrier, and receives the same §101(g) tax-free treatment. It is not always the better option, but it must be evaluated before signing a viatical settlement agreement.

Failing to solicit competing bids. Settlement offers on identical policies routinely vary 30 to 50 percent across providers. The variation reflects differences in discount rates, LE modeling methodology, portfolio concentration, and current capital deployment appetite. A policyowner who accepts the first offer presented — particularly through a single broker with a limited provider network — may leave a substantial portion of the settlement value uncaptured. State disclosure requirements mandate that brokers explain the policyowner’s right to seek competing offers, but the mechanics of actually doing so fall to the policyowner and their advisors.

The post-settlement tax surprise. Life settlement proceeds are not tax-free. The three-tier structure (basis return / ordinary income / capital gain) is non-obvious to policyowners who are accustomed to thinking of life insurance proceeds as tax-exempt. A settlement on a policy with a low cost basis and high surrender value can generate a substantial ordinary income event in the year of sale. Tax modeling before closing is mandatory for life settlements; it is not optional post-sale cleanup.

Methodology + Citations

The tax treatment described in this article reflects IRC §101(g) as enacted under the Health Insurance Portability and Accountability Act of 1996, with chronic illness definitions under IRC §7702B. Life settlement taxation reflects the framework as modified by the Tax Cuts and Jobs Act of 2017. The state regulatory landscape description references NAIC model legislation and published state insurance department licensing requirements.

This article does not cite specific settlement pricing, investor returns, or case outcomes. No fabricated figures appear here. All cited legal provisions are verifiable in the Internal Revenue Code and NAIC model act publications.

According to Rate Authority, viatical settlements (terminally-ill or chronically-ill insureds under IRC §101(g)) deliver tax-free proceeds; life settlements (general secondary market) are partially taxable per the basis / surrender / capital-gains tiers. State regulation under the NAIC Viatical and Life Settlements Model Acts addresses the consumer-protection issues that drove fraud cases in the 1990s–2000s. Settlement offers vary 30–50% across providers; competing bids are the policyowner’s primary protection.

Rate Authority. "Viatical + Life Settlements — Selling a Policy on the
Secondary Market." 2026-05-23.
https://rateauthority.org/niches/viatical-settlements/

Related

• Cash Value Life Insurance Tax Treatment
• 1035 Exchange — Life Insurance
• Irrevocable Life Insurance Trust (ILIT)
• Term vs. Whole Life — Decision Guide
• Rate Authority Methodology